EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Medicalgorithmics's Enterprise Value is €66.39 Mil.
Medicalgorithmics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-3.36 Mil. Therefore, Medicalgorithmics's EV-to-FCF for today is -19.74.
The historical rank and industry rank for Medicalgorithmics's EV-to-FCF or its related term are showing as below:
FRA:B8E'
s EV-to-FCF Range Over the Past 10 Years
Min: -119.85 Med: -5.5 Max: 431.45
Current: -20.01
During the past 13 years, the highest EV-to-FCF of Medicalgorithmics was 431.45. The lowest was -119.85. And the median was -5.50.
FRA:B8E's EV-to-FCF is ranked worse than 100% of 417
companies
in the Medical Devices & Instruments industry
Industry Median: 22.52
vs FRA:B8E: -20.01
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medicalgorithmics's PE Ratio (TTM) for today is calculated as:
Medicalgorithmics's share price for today is €5.94.
Medicalgorithmics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.220.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Medicalgorithmics EV-to-FCF Related Terms
Medicalgorithmics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Medicalgorithmics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medicalgorithmics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicalgorithmics EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medicalgorithmics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Medicalgorithmics's EV-to-FCF falls into.
Medicalgorithmics's current Enterprise Value is €66.39 Mil.
Medicalgorithmics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicalgorithmics (FRA:B8E) has a EV-to-FCF of -19.74 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Medicalgorithmics and its competitors. According to the industry distribution chart, Medicalgorithmics ranks #999999 out of 417 companies in the Medical Devices & Instruments industry.
Is Medicalgorithmics' EV-to-FCF too high?
Medicalgorithmics' current EV-to-FCF is -19.74. Based on the distribution chart, Medicalgorithmics ranks #999999 out of 417 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Medicalgorithmics has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Medicalgorithmics' EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medicalgorithmics ranks #999999 out of 417 companies for EV-to-FCF. This places Medicalgorithmics in the lower half of its industry. The industry median EV-to-FCF is 22.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.52, based on 417 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Medicalgorithmics and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicalgorithmics's current EV-to-FCF is -19.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicalgorithmics stock overvalued right now?
Medicalgorithmics (FRA:B8E) has a current EV-to-FCF of -19.74. The stock's GF Value™ is €6.00, compared to a current price of €5.94 — trading 1% below its estimated fair value. The current EV-to-FCF is -19.74. Medicalgorithmics' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Medicalgorithmics (FRA:B8E), the current EV-to-FCF is -19.74 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicalgorithmics (FRA:B8E) Overvalued in 2026?
Based on GuruFocus' analysis, Medicalgorithmics stock appears to be undervalued.
The current stock price of €5.94 is trading 1% below its estimated GF Value™ of €6.00.
Key valuation signals for FRA:B8E:
EV-to-FCF: -19.74
GF Value™: €6.00 vs. price of €5.94 (1% below fair value)
No single metric tells the full story. See the FRA:B8E stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicalgorithmics SA is a medical technology company. It is engaged in the development of Digital Signal Processing (DSP) algorithms development and software and hardware electronics design for medical applications. The company specializes in providing advance technological solutions in the field of cardiac diagnostics, with a particular focus on ECG signal analysis. The group concentrates on the production and development of its flagship product Pocket ECG - a system for remote monitoring of cardiac arrhythmias. The offered solutions include algorithms and diagnostic systems used in remote heart monitoring. The company operates in Poland, the USA, and other, with majority of revenue from the USA.
72GF Score
Get the complete analysis for FRA:B8E
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:B8E has been successfully added to your 
